These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

752 related items for PubMed ID: 17110168

  • 1. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J, de Sousa G.
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pathogen reduction of blood components.
    Solheim BG.
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [Abstract] [Full Text] [Related]

  • 4. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J, Hervig T, Putter JS.
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma.
    Smith J, Rock G.
    Transfusion; 2010 Apr; 50(4):926-31. PubMed ID: 20051060
    [Abstract] [Full Text] [Related]

  • 7. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.
    Goodrich RP, Edrich RA, Li J, Seghatchian J.
    Transfus Apher Sci; 2006 Aug; 35(1):5-17. PubMed ID: 16935562
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.
    Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R.
    Vox Sang; 2006 Feb; 90(2):85-91. PubMed ID: 16430665
    [Abstract] [Full Text] [Related]

  • 12. Update of pathogen reduction technology for therapeutic plasma.
    Chakrabarty P, Rudra S, Hoque MM.
    Mymensingh Med J; 2010 Apr; 19(2):308-11. PubMed ID: 20395932
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
    Seghatchian J, Tolksdorf F.
    Transfus Apher Sci; 2012 Apr; 46(2):221-9. PubMed ID: 22365926
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Bacterial contamination in blood components and preventative strategies: an overview.
    Vasconcelos E, Seghatchian J.
    Transfus Apher Sci; 2004 Oct; 31(2):155-63. PubMed ID: 15501419
    [Abstract] [Full Text] [Related]

  • 16. Pathogen inactivation technology: cleansing the blood supply.
    Klein HG.
    J Intern Med; 2005 Mar; 257(3):224-37. PubMed ID: 15715679
    [Abstract] [Full Text] [Related]

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 18. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
    Ambruso DR, Thurman G, Marschner S, Goodrich RP.
    Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
    [Abstract] [Full Text] [Related]

  • 19. Progress toward a pathogen-free blood supply.
    McCullough J.
    Clin Infect Dis; 2003 Jul 01; 37(1):88-95. PubMed ID: 12830413
    [Abstract] [Full Text] [Related]

  • 20. Alternative strategies in assuring blood safety: An overview.
    Epstein JS.
    Biologicals; 2010 Jan 01; 38(1):31-5. PubMed ID: 20110174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.